Accelrys Sees 14 Percent Growth in Q2 Revenues Despite Decline in Overseas Sales | GenomeWeb

Accelrys reported a 14 percent rise in Q2 revenues in spite of “disappointing” overseas sales, company officials said this week.

While the company did not provide specifics on the sales decline, officials said the Europe, Middle East, and Africa region saw a year-over-year decline and did not meet sales forecasts.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.